Latest Breaking News On - Eric ducournau - Page 1 : vimarsana.com

Atara licenses T cell therapy to Pierre Fabre for up to $640 million

As it extends its cash runway, the cell therapy developer Atara Biotherapeutics has expanded a partnership with Pierre Fabre Laboratories to commercialize the off-the-shelf T-cell therapy tabelecleucel (tab-cel) for a rare form of blood cancer.

United statesEric ducournauPierre fabreEarly access programDrug administrationBiologics license applicationMiddle eastEuropean unionPierre fabre laboratoriesCell amp gene therapiesMarkets amp regulationsT cellCell therapyPierre fabreStem cell

Pierre Fabre Laboratories to accelerate their development in onco-hematology by acquiring the license for a breakthrough T-cell immunotherapy in North America

/PRNewswire/ Pierre Fabre Laboratories announced today an expanded global partnership with Atara Biotherapeutics, a leader in T-cell immunotherapy,.

Midi pyréesUnited statesLaure sgandurraPrnewswire pierreEric ducournauPascal touchonPierre fabrePierre fabre foundationEarly access programPierre fabre laboratoriesAll remainingFabre laboratoriesTake over all manufacturingRegulatory activitiesFollowing transitionChief executive officer

Pierre Fabre Laboratories to accelerate their development in onco-hematology by acquiring the license for a breakthrough T-cell immunotherapy in North America

Pierre Fabre Laboratories to accelerate their development in onco-hematology by acquiring the license for a breakthrough T-cell immunotherapy in North America
thailand-business-news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thailand-business-news.com Daily Mail and Mail on Sunday newspapers.

Midi pyréesUnited statesPascal touchonEric ducournauEarly access programPierre fabre foundationPierre fabre laboratoriesAll remainingFabre laboratoriesTake over all manufacturingRegulatory activitiesFollowing transitionPierre fabreChief executive officerBiologics license applicationHart scott rodino antitrust improvements act

European Medicines Agency validates Pierre Fabre Laboratories marketing authorisation application for combination BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC)

European Medicines Agency validates Pierre Fabre Laboratories marketing authorisation application for combination BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaMidi pyréesEric ducournauPierre fabre laboratoriePierre fabreLaure sgandurraEuropean commissionPierre fabre foundationOno pharmaceutical co ltdWorld health organizationPfizer incEuropean medicines agencyAmerican cancer societyInternational agency for research on cancerAmerican society of clinical oncology

EU Approval Sought for Encorafenib/Binimetinib in BRAF V600+ Advanced NSCLC

The European Medicines Agency had validated a marketing authorization application seeking the approval of the combination of encorafenib and binimetinib for the treatment of adult patients with BRAF V600–mutant advanced non–small cell lung cancer.

Eric ducournauPierre fabre laboratorieEuropean medicines agencyPierre fabre laboratoriesMedicines agencyAhnm j